Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Koshy, Matthew; Malik, Renuka; Spiotto, Mike; Mahmood, Usama; Weichselbaum, Ralph; Sher, David
• Is Part Of: Journal of thoracic oncology. Volume 10:Issue 2(2015)
• Publication Date: 2015-02
• Subjects: Chest -- Cancer -- Periodicals; Thoracic Neoplasms -- Periodicals; 616.99494005
• DOI: 10.1097/JTO.0000000000000418
• Languages: English
• ISSNs: 1556-0864

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Background:</title> <p>Patients unable to receive surgery for stage I non-small cell lung cancer (NSCLC) can undergo conventional radiotherapy (ConvRT), stereotactic body radiotherapy (SBRT), or no treatment (NoTx). This study assessed patterns of care and disparities in the receipt of each of these treatments.</p> </sec> <sec> <title>Methods:</title> <p>The study included patients in the National Cancer Database from 2003 to 2011 with T1-T2N0M0 inoperable lung cancer (<italic>n</italic> = 39, 822). Logistic regressions were performed to determine predictors of receiving any radiation versus NoTx and for receiving SBRT versus ConvRT.</p> </sec> <sec> <title>Results:</title> <p>Treatment with radiation was significantly less likely in blacks (odds ratio, OR 0.65) and Hispanics (OR 0.42) compared with whites. Treatment with SBRT versus ConvRT was more likely in an academic research program (OR 2.62) and a high-volume facility (OR 7.00) compared with community cancer programs or low-volume facilities. In 2011, use of SBRT, ConvRT, and NoTx was 25%, 28%, and 46% for patients in a community cancer center versus 68%, 11%, and 21%, respectively, in an academic center (<italic>p</italic> < 0.0001).</p> </sec> <sec> <title>Conclusion:</title> <p>There were marked institutional and socioeconomic variations in the treatment of inoperable stage I NSCLC. These results suggest that removal of barriers to receive radiation therapy and particularly improved access to SBRT may meaningfully improve survival in this disease.</p> </sec> </abstract>